• Profile
Close

Omalizumab treatment patterns among patients with asthma in the US Medicare population

The Journal of Allergy and Clinical Immunology: In Practice Jul 25, 2019

Li P, et al. - Among US Medicare beneficiaries with asthma who initiated omalizumab therapy, researchers assessed the characteristics and treatment patterns as well as factors related to discontinuation and adherence to omalizumab. In this retrospective claims database analysis, omalizumab continuation and adherence to this therapy was reported among over 60% of Medicare patients with asthma during a 12-month follow-up. Factors related to treatment adherence and discontinuation were patient age, low-income subsidy (LIS) status, and the numbers of evaluation and management physician visits. Significantly lower odds of discontinuation and higher odds of adherence were reported in patients aged 65–69 and 70–74 years vs those aged ≥ 80 years. Lower odds of discontinuation and higher odds of adherence were reported in non-LIS patients vs patients receiving LIS. Also, lower odds of discontinuation and higher odds of adherence were reported in relation to greater numbers of pre-index evaluation and management physician visits and comorbid rhinitis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay